The Blood Neutrophil-to-lymphocyte Ratio Predicts Survival in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib |
Zheng, You-Bing
(Department of Interventional Radiology, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences)
Zhao, Wei (Department of Interventional Radiology, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences) Liu, Bing (Department of Interventional Radiology, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences) Lu, Li-Gong (Department of Interventional Radiology, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences) He, Xu (Department of Interventional Radiology, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences) Huang, Jian-Wen (Department of Interventional Radiology, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences) Li, Yong (Department of Interventional Radiology, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences) Hu, Bao-Shan (Department of Interventional Radiology, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences) |
1 | Abou-Alfa GK, Schwartz L, Ricci S, et al (2006). Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol, 24, 4293-300 DOI ScienceOn |
2 | Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2 DOI ScienceOn |
3 | Carlomagno F, Anaganti S, Guida T, et al (2006). BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst, 98, 326-34 DOI ScienceOn |
4 | Chen TM, Lin CC, Huang PT, Wen CF (2012). Neutrophilto- lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol, 27, 553-61 DOI ScienceOn |
5 | Cheng AL, Kang YK , Chen Z, et al (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol, 10, 25-34 DOI ScienceOn |
6 | Chew V, Tow C, Teo M, et al (2010). Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol, 52, 370-9 |
7 | Cho JY, Paik YH, Lim HY, et al (2013). Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Liver Int, 33, 950-7 DOI ScienceOn |
8 | Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-7 DOI ScienceOn |
9 | Ding PR, An X, Zhang RX, et al (2010). Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis, 25, 1427-33 DOI |
10 | Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55 DOI ScienceOn |
11 | Gomez D, Farid S, Malik HZ, et al (2008). Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg, 32, 1757-62 DOI |
12 | Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-74 DOI ScienceOn |
13 | Hsu CH, Shen YC, Lin ZZ, et al (2010). Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol, 53, 126-31 DOI ScienceOn |
14 | Hung HY, Chen JS, Yeh CY, et al (2011). Effect of preoperative neutrophil-lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy. Int J Colorectal Dis, 26, 1059-65 DOI |
15 | Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH (2003). Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis, 6, 283-7 DOI |
16 | Limaye AR, Clark V, Soldevila-Pico C, et al (2012). Neutrophillymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma. Hepatol Res, 43, 757-64. |
17 | Iavarone M, Cabibbo G, Piscaglia F, et al (2011). Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology, 54, 2055-63 DOI ScienceOn |
18 | Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ (2000). Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxidedependent mechanism. Cancer Res, 60, 184-90 |
19 | Kuang DM, Zhao Q, Wu Y, et al (2011). Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol, 54, 948-55 DOI ScienceOn |
20 | Llovet JM, Ricci S, Mazzaferro V, et al (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359, 378-90 DOI ScienceOn |
21 | McDonald B, Spicer J, Giannais B, et al (2009). Systemic inflammation increases cancer cell adhesion to hepatic sinusoids by neutrophil mediated mechanisms. Int J Cancer, 125, 1298-305 DOI ScienceOn |
22 | McNally ME, Martinez A, Khabiri H, et al (2013). Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. Ann Surg Oncol, 20, 923-8 DOI ScienceOn |
23 | Minguez B, Lachenmayer A (2011). Diagnostic and prognostic molecular markers in hepatocellular carcinoma. Dis Markers, 31, 181-90 DOI |
24 | Motomura T, Shirabe K, Mano Y, et al (2013). Neutrophillymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol, 58, 58-64 DOI ScienceOn |
25 | Vincenzi B, Santini D, Russo A, et al (2010). Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist, 15, 85-92 DOI ScienceOn |
26 | Ohtani H (2007). Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun, 7, 4 |
27 | Prete SD, Montella L, Caraglia M, et al (2010). Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So LAR study. Cancer Chemother Pharmacol, 66, 837-44 DOI |
28 | Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16 DOI ScienceOn |
29 | Wilhelm S, Chien DS (2002). BAY 43-9006: preclinical data. Curr Pharm Des, 8, 2255-7 DOI ScienceOn |
30 | Halazun KJ, Hardy MA, Rana AA, et al (2009). Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg, 250, 141-51 DOI ScienceOn |
31 | Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T (1997). Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol, 15, 826-32 DOI |